The Scientific Journey Behind Ozempic (with L...

Andrew Ross Sorkin does the work of about five people. He founded and writes the DealBook newsletter for the New York Times. He hosts Squawk Box on CNBC every morning at 6am. He runs the DealBook Summit, which has become the premier annual interview event across business, policy, ...  Show more

Tobi is one of the most thoughtful people in the technology industry. He's also one of the very few people who started as a programmer -- just trying to solve his own problem -- and still runs his company as CEO today even as it approaches a $200B market cap. Tobi has done this i ...  Show more

Ozempic is one of the most important new medications in a generation. The driving force behind it is the Danish pharmaceutical company Novo Nordisk, which has been invested in GLP-1 research since the early 1990s. The leading scientist in this domain, a self-described "nerd," ...

Today we’re presenting Trillion Dollar Shot, a new series that explores the business story behind the rise of Ozempic and other blockbuster drugs being used for weight loss. The first episode focuses on the Novo Nordisk scientist who invented the compound that paved the way for O ...  Show more

Weight-loss drugs have become a golden formula for pharma growth. In this episode we speak to Sector Advisor Maria Latorre and Senior Economist Michaela Grimm about how GLP-1 treatments like Ozempic and Wegovy are reshaping the industry, and the risks that lie ahead. SHOWNOTES: • ...  Show more

Diabetes and obesity drugs like Ozempic, Wegovy and Mounjaro have become famous for helping users shed big amounts of weight. It's a market that could soon be worth more than $100 billion. Two companies dominate this space, Novo Nordisk which makes Ozempic and Eli Lilly, maker of ...  Show more